652156-53-1

Basic information

• Product Name: 1-Piperazinecarboxamide, N-methyl-4-(phenylmethyl)-
• CAS NO: 652156-53-1
• Molecular Formula: C13H19N3O
• Molecular Weight: 233.313
• Mol File: 652156-53-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxamide, N-methyl-4-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxamide, N-methyl-4-(phenylmethyl)-(652156-53-1)
• EPA Substance Registry System: 1-Piperazinecarboxamide, N-methyl-4-(phenylmethyl)-(652156-53-1)

Safety Data

• Hazardous Substances Data: 652156-53-1(Hazardous Substances Data)

Usage

Purpose

Anti-obesity drug

Mechanism

Activates serotonin receptors in the brain to promote a feeling of fullness and reduce food intake

Target users

Adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater who have at least one weight-related condition (e.g. high blood pressure, type 2 diabetes, or high cholesterol)

Potential risks

Increased risk of certain cancers

Market status

Withdrawn from the market in some countries

Upstream product

• 2759-28-6 1-phenylmethylpiperazine 
• 1885-14-9 phenyl chloroformate 
• 74-89-5 methylamine 
• 624-83-9 methyl isocyanate 
• 1943-79-9 N-Methyl-O-phenylcarbamat 

Downstream Products

• 163361-25-9 N-methyl-1-piperazinecarboxamide 

Relevant articles and documents

PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES

-

Active salt forms with tyrosine kinase activity

The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

Salt forms with tyrosine kinase activity

The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.